» Articles » PMID: 15208521

Assessing and Managing Breast Cancer Risk: Clinical Tools for Advising Patients

Overview
Journal MedGenMed
Specialty General Medicine
Date 2004 Jun 23
PMID 15208521
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Using breast cancer risk assessment tools and going through the process of assessing breast cancer risk can answer many women's questions about what puts them at relatively higher or lower risk. This effectively engages both the clinician and the patient in a discussion about breast cancer, the chances of getting it, and the family's involvement--making the process as important as the actual tools. Examples of selected case histories demonstrate risk assessment using available tools such as the Gail-NCI and the Claus models. For some women, such as those considering tamoxifen or prophylactic surgeries, it may be desirable to prescreen for the inheritance of hereditary mutations and to follow with genetic testing, if indicated. Testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. The literature contains general interventions that are widely accepted to reduce the severity and the burden of breast cancer, and these are brought together here. The risk assessment process is an important part of a risk reduction program and can help motivate women to engage in prevention activities. This paper uses 2 hypothetical but fact-based and typical case histories to discuss the utility of risk assessment tools for informing women about their options.

Citing Articles

Developing a risk prediction model for breast cancer: a Statistical Utility to Determine Affinity of Neoplasm (SUDAN-CA Breast).

Salih A, Alam-Elhuda D, Alfaki M, Yousif A, Nouradyem M Eur J Med Res. 2017; 22(1):35.

PMID: 28962650 PMC: 5622480. DOI: 10.1186/s40001-017-0277-6.


Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?.

Sardanelli F, Podo F Eur Radiol. 2006; 17(4):873-87.

PMID: 17008989 DOI: 10.1007/s00330-006-0389-9.

References
1.
de Bock G, Vliet Vlieland T, Hageman G, Oosterwijk J, Springer M, Kievit J . The assessment of genetic risk of breast cancer: a set of GP guidelines. Fam Pract. 1999; 16(1):71-7. DOI: 10.1093/fampra/16.1.71. View

2.
Willett W, Dietz W, Colditz G . Guidelines for healthy weight. N Engl J Med. 1999; 341(6):427-34. DOI: 10.1056/NEJM199908053410607. View

3.
Gail M, Costantino J, Bryant J, Croyle R, Freedman L, Helzlsouer K . Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999; 91(21):1829-46. DOI: 10.1093/jnci/91.21.1829. View

4.
Eisinger F, Julian-Reynier C, Sobol H, Stoppa-Lyonnet D, Lasset C, Nogues C . Acceptability of prophylactic mastectomy in cancer-prone women. JAMA. 2000; 283(2):202-3. DOI: 10.1001/jama.283.2.202. View

5.
Armstrong K, Eisen A, Weber B . Assessing the risk of breast cancer. N Engl J Med. 2000; 342(8):564-71. DOI: 10.1056/NEJM200002243420807. View